Progress on integrated treatment of adenocarcinoma of esophagogastric junction
- VernacularTitle:局部晚期食管-胃结合部腺癌的综合治疗进展
- Author:
Jiadi WU
1
,
2
,
3
,
4
,
5
;
Yan HUANG
1
,
2
,
3
,
4
,
5
;
Caiyan FANG
1
,
2
,
3
,
4
,
5
;
Hong YANG
1
,
2
,
3
,
4
,
5
Author Information
1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center,
2. State Key Laboratory of Oncology in South China,
3. Guangdong Esophageal Cancer Institute,
4. Collaborative Innovation Center for Cancer
5. Medicine, Guangzhou, 510060, P. R. China
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma of esophagogastric junction;
integrated treatment;
evidence-based medicine;
review
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(02):251-256
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is an accepted standard in the treatment of adenocarcinoma of esophagogastric junction (AEG), but the efficacy of surgery alone for locally advanced AEG is limited. In-depth studies concerning combined therapy for AEG have been carried out worldwide, including neoadjuvant chemotherapy (nCT), neoadjuvant chemoradiotherapy (nCRT), perioperative chemotherapy (pCT), postoperative chemoradiotherapy, etc. Significantly, the contribution of nCRT and pCT to improving the prognosis of locally advanced AEG patients has been shed light on. Compared with that, multimodality treatment for AEG patients is not well established in China. An attempt was thus made to take an overview of the evidence-based research advance regarding integrated therapy of AEG.
